뉴옵틱스

비상장계속사업자

NEW OPTICS. LTD

이영득

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

뉴옵틱스

Business Reg. No. 1278194175 · CEO 이영득

I.Investment Overview

Target뉴옵틱스 (1278194175)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명뉴옵틱스
영문명NEW OPTICS. LTD
대표자이영득
사업자등록번호1278194175
법인등록번호2801110070810
설립일2005.08.02
종업원수192명

V.Workforce

192

Current headcount · 2026.06 as of

VI.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW1,9952025
영업이익100M KRW1.22025
순이익100M KRW1512025
Item20252024202320222021
자산총계1,920.2억원1,716.4억원1,331.6억원1,500.7억원1,501억원
부채총계1,157.3억원1,112.7억원762.6억원956.5억원1,052.3억원
자본총계762.9억원603.7억원568.9억원544.2억원448.7억원
매출액1,995억원
영업이익1.2억원
순이익151억원

VII.Financial Ratios

FY2025 basis

0.06%

영업이익률

7.57%

순이익률

7.86%

ROA

19.79%

ROE

151.71%

부채비율

39.73%

자기자본비율

VIII.R&D Activity

Fields 보건의료 > 의료기기 · 전기/전자 > 디스플레이 · 재료 > 고분자재료

Keywords 유세포분석, 혈구계수기, 듀얼 레이저, 현미경영상진단기기, 초소수성

YearProjectsPapersPatents
2020001
2019103
2018104
20172010
20162312
20154011
2014200

IX.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

뉴옵틱스 투심보고서 | Alpha Lenz